---
layout: post
title: "Pharmacyclics LLC.; Withdrawal of Approval of Indications for Mantle Cell Lymphoma and Marginal Zone Lymphoma for IMBRUVICA (ibrutinib) Capsules and Tablets"
date: 2026-02-05 18:57:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-27662
original_published: 2023-12-18 00:00:00 +0000
significance: 8.00
---

# Pharmacyclics LLC.; Withdrawal of Approval of Indications for Mantle Cell Lymphoma and Marginal Zone Lymphoma for IMBRUVICA (ibrutinib) Capsules and Tablets

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** December 18, 2023 00:00 UTC
**Document Number:** 2023-27662

## Summary

The Food and Drug Administration (FDA or Agency) is announcing that it is withdrawing approval of the indications for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) for IMBRUVICA (ibrutinib) Capsules and Tablets approved, respectively, under new drug applications (NDAs) 205552 and 210563. These NDAs are held by Pharmacyclics LLC, 1000 Gateway Blvd., South San Francisco, CA 94080 (Pharmacyclics). Pharmacyclics voluntarily requested that the Agency withdraw approval of these indications and waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/18/2023-27662/pharmacyclics-llc-withdrawal-of-approval-of-indications-for-mantle-cell-lymphoma-and-marginal-zone)
- API: https://www.federalregister.gov/api/v1/documents/2023-27662

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
